Nothing Special   »   [go: up one dir, main page]

CO6321246A2 - Compuestos novedosos activos como antagonistas de receptor muscarinico - Google Patents

Compuestos novedosos activos como antagonistas de receptor muscarinico

Info

Publication number
CO6321246A2
CO6321246A2 CO10160882A CO10160882A CO6321246A2 CO 6321246 A2 CO6321246 A2 CO 6321246A2 CO 10160882 A CO10160882 A CO 10160882A CO 10160882 A CO10160882 A CO 10160882A CO 6321246 A2 CO6321246 A2 CO 6321246A2
Authority
CO
Colombia
Prior art keywords
novedous
compounds
active new
muscarinic
receiver antagonists
Prior art date
Application number
CO10160882A
Other languages
English (en)
Inventor
Paul Alan Glossop
Lane Charlotte Alice Louise
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of CO6321246A2 publication Critical patent/CO6321246A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La invención se relaciona con derivados del éster piperidin-4-il del ácido bifenil-2-il-carbámico, procesos e intermediarios para su preparación, y composiciones farmacéuticas que los contienen, útiles como antagonistas muscarínicos.
CO10160882A 2008-07-15 2010-12-22 Compuestos novedosos activos como antagonistas de receptor muscarinico CO6321246A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8072608P 2008-07-15 2008-07-15

Publications (1)

Publication Number Publication Date
CO6321246A2 true CO6321246A2 (es) 2011-09-20

Family

ID=41139473

Family Applications (1)

Application Number Title Priority Date Filing Date
CO10160882A CO6321246A2 (es) 2008-07-15 2010-12-22 Compuestos novedosos activos como antagonistas de receptor muscarinico

Country Status (28)

Country Link
US (1) US20100016366A1 (es)
EP (1) EP2328868A1 (es)
JP (1) JP2011528346A (es)
KR (1) KR20110017452A (es)
CN (1) CN102099334A (es)
AP (1) AP2010005512A0 (es)
AR (1) AR072802A1 (es)
AU (1) AU2009272303B2 (es)
BR (1) BRPI0915753A2 (es)
CA (1) CA2727769A1 (es)
CL (1) CL2011000093A1 (es)
CO (1) CO6321246A2 (es)
CR (1) CR11828A (es)
DO (1) DOP2011000017A (es)
EA (1) EA201001842A1 (es)
EC (1) ECSP11010753A (es)
HN (1) HN2009001330A (es)
IL (1) IL210293A0 (es)
MA (1) MA32479B1 (es)
MX (1) MX2011000588A (es)
NI (1) NI201100015A (es)
NZ (1) NZ589934A (es)
PE (1) PE20110312A1 (es)
SV (1) SV2011003808A (es)
TW (1) TW201006799A (es)
UY (1) UY31980A (es)
WO (1) WO2010007552A1 (es)
ZA (1) ZA201100841B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011083387A1 (en) * 2010-01-07 2011-07-14 Pfizer Limited Hydrochloride salt of biphenyl-2-yl-carbamic acid 1-{9-[(3-fluoro-4-hydroxy-benzoyl)-methyl-amino]-nonyl}-piperidin-4-yl ester
RU2012143704A (ru) * 2010-04-01 2014-05-10 Теравида, Инк. Способы улучшения качества сна
CN107074816B (zh) * 2015-03-27 2020-07-17 四川海思科制药有限公司 一种杂环衍生物及其制备方法和在医药上的用途
CN107108562B (zh) * 2015-05-14 2020-07-10 四川海思科制药有限公司 具有β2受体激动及M受体拮抗活性的含氮杂螺环衍生物及其在医药上的用途
CN106336406B (zh) * 2015-07-10 2020-01-03 四川海思科制药有限公司 具有β2受体激动及M受体拮抗活性的八氢并环戊二烯衍生物及其在医药上的用途
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
KR20200066655A (ko) 2017-10-05 2020-06-10 풀크럼 쎄러퓨틱스, 인코포레이티드 DUX4의 발현을 저감시키기 위한 p38 저해제의 용도

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20040950A1 (es) * 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
JP2009534463A (ja) * 2006-04-24 2009-09-24 アストラゼネカ・アクチエボラーグ 例えば慢性気管支閉塞、喘息および過活動膀胱の処置に有用な、ムスカリンｍ３受容体アンタゴニスト活性を有する環状アミノアルコールの新規アルキルエステル

Also Published As

Publication number Publication date
UY31980A (es) 2010-02-26
CL2011000093A1 (es) 2011-05-06
NI201100015A (es) 2011-08-05
AU2009272303B2 (en) 2011-12-22
JP2011528346A (ja) 2011-11-17
HN2009001330A (es) 2012-04-02
EA201001842A1 (ru) 2011-08-30
CN102099334A (zh) 2011-06-15
US20100016366A1 (en) 2010-01-21
ZA201100841B (en) 2011-10-26
AR072802A1 (es) 2010-09-22
WO2010007552A1 (en) 2010-01-21
TW201006799A (en) 2010-02-16
AP2010005512A0 (en) 2010-12-31
CA2727769A1 (en) 2010-01-21
EP2328868A1 (en) 2011-06-08
KR20110017452A (ko) 2011-02-21
ECSP11010753A (es) 2011-02-28
CR11828A (es) 2011-01-10
BRPI0915753A2 (pt) 2015-11-03
SV2011003808A (es) 2011-03-23
PE20110312A1 (es) 2011-06-25
IL210293A0 (en) 2011-03-31
MX2011000588A (es) 2011-03-01
AU2009272303A1 (en) 2010-01-21
DOP2011000017A (es) 2011-02-15
NZ589934A (en) 2012-06-29
MA32479B1 (fr) 2011-07-03

Similar Documents

Publication Publication Date Title
CO6480918A2 (es) Antagonistas policíclicos de receptores de ácido lisofosfatídico.
ECSP11011517A (es) Compuestos antivirales
CR20120113A (es) (heteroarilmetil)tiohidantoinas sustituidas como drogas anticancer
CR20150296A (es) Novedosos derivados de bencimidazol como antagonistas de ep4
CO6362015A2 (es) Derivados de acido 1-amino-2ciclobutiletilboronico
CR20110028A (es) Derivados de pirimidina como inhibidores de cinasa
UY33735A (es) Compuestos antivirales
UY29798A1 (es) Derivados de carboxamida como antagonistas del receptor muscarínico
CL2012000921A1 (es) Compuestos derivados de espiropiperidina-metilbenciloxifenil, activadores del receptor rpg-40; composicion farmaceutica que los comprende; y uso del compuesto para tratar diabetes.
EA201290940A1 (ru) Новые соединения как селективные антагонисты рецептора nk3, фармацевтическая композиция и методы их использования при нарушениях, опосредованных nk3 рецепторами
UY32036A (es) Derivados de ciclohexil-amida, composiciones farmacéuticas que los contienen, su preparación y aplicaciones
CO6321246A2 (es) Compuestos novedosos activos como antagonistas de receptor muscarinico
CL2011003147A1 (es) Compuestos derivados de n-(1-4-(1h-pirazol-5-il)ftalazina-1-il) piperidina-4-il) benzamida; composicion farmaceutica que los contiene, utiles como antagonista de la trayectoria de hedgehog, en el tratamiento del cancer.
ECSP14013327A (es) Compuestos con actividad nematicida
CO6351723A2 (es) Derivados de pirazolo-[5,1-b]-oxazol como antagonistas de crf1
EA201101116A1 (ru) Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина
BR112015012720A2 (pt) derivados de feniletilpiridina como inibidores de pde4
EA201101118A1 (ru) Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина
BR112015012716A2 (pt) derivados de feniletilpiridina como inibidores de pde4
CO6321288A2 (es) Sales de compuestos inhibidores de vih
CL2010000253A1 (es) Procedimiento de preparacion de ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable; y uno de los compuestos intermediarios considerados.
UY32744A (es) Derivados de 2-carboxamida-7-piperazinil-benzofurano 774
ATE546448T1 (de) Urotensin-ii-rezeptorantagonisten
CL2011003123A1 (es) Compuestos derivados de ciclopentanamida sustituidos; composicion farmaceutica; proceso de obtencion; y uso en el tratamiento o la profilaxis de la diabetes, aterosclerosis, entre otras.
UY31338A1 (es) Compuestos novedosos activos como antagonistas de receptores muscarinicos

Legal Events

Date Code Title Description
FA Application withdrawn